ReviewHistopathology2022
An introduction to the WHO 5th edition 2022 classification of testicular tumours.
Review in Histopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Guideline
- From Testis to Retroperitoneum: The Role of Radiomics and Artificial Intelligence for Primary Tumors and Nodal Disease in Testicular Cancer: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Myoid Gonadal Stromal Tumor of the Testis: A Rare Sex Cord-Stromal Neoplasm in a Young Man.Cureus · 2026Article
- Immunohistochemical characterization of somatically derived "yolk sac tumors": analysis of a multi-institutional case series.Virchows Archiv : an international journal of pathology · 2026Article
- Primary testicular neuroendocrine tumor: Diagnostic challenges and WHO 2022 classification insights.The Journal of international medical research · 2026Article
- Single-cell and spatial transcriptome analysis reveals the potential therapeutic targets for testicular sex cord-stromal cell tumor.Biomarker research · 2026Article
- Identification and validation of liquid biopsy-based methylation biomarkers for germ cell tumor subtypes.Communications medicine · 2026Article
- Sertoli cell tumor in familial adenomatous polyposis: a case report.Frontiers in oncology · 2026Article
- Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?Frontiers in surgery · 2026Article
- A Retrospective Analysis of Testicular Cancer (2007-2025): A Single Institutional Experience.Research and reports in urology · 2026Article
- Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours.Andrology · 2026Article
- Testicular intestinal-type adenocarcinoma without an identifiable extratesticular primary site: a case report and literature review.Frontiers in oncology · 2026Article
- Advances in non-germ cell tumours of the testis: focus on new molecular developments in sex cord-stromal tumours.Histopathology · 2026Review
- Low-grade glial neoplasms of germ cell origin may represent maturation of embryonic-type neuroectodermal elements.Histopathology · 2026Article
- Synthesis, characterization, and anticancer evaluation of nano-sized schiff base metal chelates.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025Article
- Article
- First application of three-dimensional light sheet fluorescence microscopy to human testicular tumors: New perspectives in histopathology.Andrology · 2025Article
- Clinicopathological characteristics and molecular genetic analysis of inflammatory and nested testicular sex cord tumor: a case report and literature review.Discover oncology · 2025Article
- Prepubertal testicular neuroendocrine tumor in postpubertal males: a case report and review of the literature.Journal of medical case reports · 2025Review
- Testicular Neoplasms and Other Abnormalities in Common CarpAnimals : an open access journal from MDPI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 15 institutions in 10 countries.
Funding
Abstract
The 5th edition of the World Health Organisation Blue Book was published recently and includes a comprehensive update on testicular tumours. This builds upon the work of the 4th edition, retaining its structure and main nomenclature, including the use of the term 'germ cell neoplasia in situ' (GCNIS) for the pre-invasive lesion of most germ cell tumours and division from those not derived from GCNIS. While there have been important developments in understanding the molecular underpinnings of testicular cancer, this updated classification paradigm and approach remains rooted in morphology. Nomenclature changes include replacement of the term 'primitive neuroectodermal tumour' by 'embryonic neuroectodermal tumour' based on the non-specificity of the former term and to separate these tumours clearly from Ewing sarcoma. Seminoma is placed in a germinoma family of tumours emphasising relation to those tumours at other sites. Criteria for the diagnosis of 'teratoma with somatic transformation' have been modified to not include variable field size assessments. The word 'carcinoid' has been changed to 'neuroendocrine tumour', with most examples in the testis now classified as 'prepubertal type testicular neuroendocrine tumour'. For sex cord-stromal tumours, the use of mitotic counts per high-power field has been changed to per mm2 for malignancy assessments, and the new entities, 'signet ring stromal tumour' and 'myoid gonadal stromal tumour', are defined. Well-differentiated papillary mesothelial tumour has now been defined as tumour type with a favourable prognosis. Sertoliform cystadenoma has been removed as an entity from testicular adnexal tumours and placed with Sertoli cell tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.